Amarin Corp Plc (AMRN)

[Atom0aks]

So what were the NLA suggested guidelines .... diagnosed ASCVD and diabetics with one additional risk factor ?

You don’t think that will be the voting question .... and how many millions of patients does that cover ?

That is still a huge label
JMO
Kiwi

The NLA's position statement is (emphasis is mine),

For patients 45 years of age or older with clinical ASCVD, or 50 years of age or older with type 2 diabetes requiring medication and >1 additional risk factor*, and fasting triglycerides 135-499 mg/dL on maximally tolerated statin, with or without ezetimibe, treatment with icosapent ethyl is recommended for ASCVD risk reduction.

Source: https://www.lipid.org/nla/nla-position-use-icosapent-ethyl-high-and-very-high-risk-patients